Since the discovery of HBV in the 1960s, its life cycle and the natural history of infection have been delineated by many studies. In 2014, new findings concerning the host–virus interaction and new studies of HBV reactivation from occult HBV infection are of considerable interest.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model
BMC Genomics Open Access 22 August 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1, e00049 (2012).
Yan, H. et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J. Virol. 6, 3273–3284 (2014).
Watashi, K. et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59, 1726–1737 (2014).
Ni, Y. et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146, 1070–1083 (2014).
Urban, S., Bartenschlager, R., Kubitz, R. & Zoulim, F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147, 48–64 (2014).
Michalak, T. I., Pasquinelli, C., Guilhot, S. & Chisari, F. V. Hepatitis B virus persistence after recovery from acute viral hepatitis. J. Clin. Invest. 93, 230–239 (1994).
Dervite, I., Hober, D. & Morel, P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med. 344, 68–69 (2001).
Evens, A. M. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann. Oncol. 22, 1170–1180 (2011).
Hsu, C. et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 59, 2092–2100 (2014).
Seto, W. K. et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J. Clin. Oncol. 32, 3736–3743 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.-F.Y. is member of advisory boards and/or speaker's bureau for Abbvie, Bristol–Myers Squibb, Gilead, GlaxoSmithKline, Janssen Pharmaceutica and Roche Diagnostics. L.-C.L. is a member of advisory boards and/or speaker's bureau for Arrowhead Research, Bristol–Myers Squibb and Gilead.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Yuen, MF., Lai, CL. HBV research moves forward—receptors and reactivation. Nat Rev Gastroenterol Hepatol 12, 70–72 (2015). https://doi.org/10.1038/nrgastro.2014.226
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.226
This article is cited by
-
Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection
Current Hepatology Reports (2022)
-
Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model
BMC Genomics (2017)
